Literature DB >> 18497552

[Increased pulmonary artery stiffness and its relation to right ventricular function in patients with systemic lupus erythematosus].

Dursun Duman1, Seval Masatlioğlu, Refik Demirtunç, Bilgehan Karadağ.   

Abstract

OBJECTIVES: Pulmonary hypertension and right ventricular (RV) dysfunction are severe complications of systemic lupus erythematosus (SLE). The role of increased pulmonary artery stiffness (PAS) has not been studied in RV dysfunction. We investigated the relationship between PAS and RV function in SLE patients without cardiovascular symptoms. STUDY
DESIGN: The study included 32 patients with SLE (30 males, 2 females; mean age 34+/-9 years) and 30 age- and sex-matched healthy controls (28 males, 2 females; mean age 36+/-5 years). All the subjects underwent echocardiographic examination. Using Doppler echocardiography, PAS was calculated by dividing maximal frequency shift of the pulmonary flow by the acceleration time. To assess RV function, RV myocardial performance index (MPI) was determined by the sum of isovolumetric contraction and relaxation times divided by the ejection time. In addition, tricuspid annular plane systolic excursion (TAPSE) was measured on two-dimensional M-mode recordings.
RESULTS: Compared to the control group, patients with SLE exhibited significantly higher PAS (p=0.004) and RV MPI (p=0.001), and lower TAPSE (p=0.001). In univariate correlation analysis, SV MPI was significantly correlated with PAS (r=0.60, p=0.001), age (r=0.48, p=0.003), SLE duration (r=0.51, p=0.002), and pulmonary artery systolic pressure (r=0.36, p=0.03). Multivariate linear regression analysis showed that PAS (95% CI 0.002-0.005; p=0.001) and SLE duration (95% CI 0.001-0.004; p=0.004) were independently associated with RV MPI. In addition, a significant inverse relationship was found between TAPSE and RV MPI (r= -0.48, p=0.005). Twenty-four SLE patients had normal RV function (TAPSE > or = 17 mm). Eight patients with RV dysfunction (TAPSE <17 mm) had significantly different RV MPI (p=0.001), PAS (p=0.002), age (p=0.04), and SLE duration (p=0.004).
CONCLUSION: Our data suggest that increased PAS is strongly associated with the development of RV dysfunction in patients with SLE.

Entities:  

Mesh:

Year:  2008        PMID: 18497552

Source DB:  PubMed          Journal:  Turk Kardiyol Dern Ars        ISSN: 1016-5169


  5 in total

1.  The implication of tissue Doppler echocardiography and cardiopulmonary exercise in early detection of cardiac dysfunction in systemic lupus erythematosus patients.

Authors:  Basant M Elnady; Ayman Saeed Mohamed Abdelghafar; El Shazly Abdul Khalik; Mohammed Mesfer Algethami; A S Basiony; Mona Dhaif Allah Al-Otaibi; Maram Eidhah Al-Otaibi
Journal:  Eur J Rheumatol       Date:  2016-09-01

2.  Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.

Authors:  Mustafa Yenerçağ; Uğur Arslan; Seçkin Dereli; Metin Çoksevim; Mustafa Doğduş; Ahmet Kaya
Journal:  Int J Cardiovasc Imaging       Date:  2020-08-19       Impact factor: 2.357

3.  Relationship between Pulmonary Artery Stiffness and Functional Capacity in Patients with Heart Failure with Reduced Ejection Fraction.

Authors:  Erkan Yildirim; Murat Celik; Uygar Cagdas Yuksel; Mutlu Gungor; Baris Bugan; Deniz Dogan; Yalcin Gokoglan; Hasan Kutsi Kabul; Suat Gormel; Salim Yasar; Mustafa Koklu; Cem Barcin
Journal:  Korean Circ J       Date:  2017-11-06       Impact factor: 3.243

4.  Pulmonary arterial hemodynamic assessment by a novel index in systemic lupus erythematosus patients: pulmonary pulse transit time.

Authors:  Tolga Han Efe; Mehmet Doğan; Cem Özişler; Tolga Çimen; Mehmet Ali Felekoğlu; Ahmet Göktuğ Ertem; Engin Algül; Sadık Açıkel
Journal:  Anatol J Cardiol       Date:  2017-06-22       Impact factor: 1.596

5.  Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction.

Authors:  Sencer Çamcı; Emre Yılmaz
Journal:  Medicina (Kaunas)       Date:  2022-08-19       Impact factor: 2.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.